Short-Term Traders Descend On Intrexon Corporation (XON)

Intrexon Corp (XON) is surging on a deal with Merck Serono

Digital Content Group

Mar 30, 2015 at 11:00 AM

Intrexon Corp (NYSE:XON) has shot 5.3% higher to $45.26, after the company announced a collaboration with Merck Serono -- the biopharmaceutical business of Germany's Merck KGaA* -- to develop and commercialize various cancer therapies. As such, XON options are flying off the shelves at 10 times the expected intraday pace.

Most active is the April 40 call. It appears traders are both buying to open and selling to close positions here.

Longer term, XON has advanced upwards of 64% on a year-to-date basis. In fact, during the past 60 sessions, the stock has outperformed the broader S&P 500 Index (SPX) by a brow-raising 56 percentage points.

As such, call buying has been in vogue. Intrexon Corp's (NYSE:XON) 10-day call/put volume ratio across the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) is 13.91 -- with nearly 14 calls bought to open for every put during the past two weeks. Historically speaking, this ratio outstrips more than three-quarters of all comparable readings from the previous year.

*The original text of this post described Merck Serono as a unit of Merck & Co., Inc. (NYSE:MRK). We regret the error.

Follow @Schaeffers

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released!